Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Platinum-sensitive Relapsed Epithelial Ovarian Cancer”

63 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 63 results

Large-scale testing (Phase 3)Not Yet RecruitingNCT07816666
What this trial is testing

Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer

Who this might be right for
Platinum-sensitive Relapsed Epithelial Ovarian CancerPlatinum-sensitive Relapsed Fallopian Tube CancerPlatinum-sensitive Relapsed Primary Peritoneal Cancer
AstraZeneca 600
Testing effectiveness (Phase 2)Study completedNCT02289950
What this trial is testing

Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Participants With Low CA125 Platinum-sensitive Ovarian Cancer

Who this might be right for
Platinum-Sensitive Ovarian Cancer in First Relapse
Eisai Inc. 332
Not applicableStudy completedNCT03505307
What this trial is testing

Lynparza Ovarian Cancer Clinical Experience Investigation (All Case Investigation)

Who this might be right for
Ovarian Cancer
AstraZeneca 846
Early research (Phase 1)UnknownNCT04029909
What this trial is testing

A Clinical Study of Gimatecan in Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer

Who this might be right for
Ovarian Epithelial CancerFallopian Tube CancerPrimary Peritoneal Cancer
Lee's Pharmaceutical Limited 12
Large-scale testing (Phase 3)Study completedNCT02282020
What this trial is testing

Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments

Who this might be right for
Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
AstraZeneca 266
Testing effectiveness (Phase 2)Study completedNCT01482715
What this trial is testing

Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)

Who this might be right for
Ovarian CancerFallopian Tube CancerPeritoneal Cancer+1 more
pharmaand GmbH 136
Large-scale testing (Phase 3)Ended earlyNCT00189371
What this trial is testing

Reinduction Chemotherapy Containing Carboplatin and Paclitaxel With or Without Epoetin Alpha in Recurrent Platinum Sensitive Ovarian Cancer, Cancer of the Fallopian Tube or Peritoneum

Who this might be right for
Epithelial Ovarian Cancer, Fallopian Tube or PeritoneumPlatinum Sensitve RelapseAnemia
AGO Study Group 300
Large-scale testing (Phase 3)Study completedNCT03534453
What this trial is testing

Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

Who this might be right for
Relapsed Ovarian CancerFollowing Complete or Partial Response to Platinum Based ChemotherapyPlatinum Sensitive
AstraZeneca 229
Early research (Phase 1)Study completedNCT01281514
What this trial is testing

Carboplatin, PLD and Everolimus in Certain Gynecologic Cancer

Who this might be right for
Fallopian Tube CancerPeritoneal Cavity CancerRecurrent Ovarian Epithelial Cancer
Fox Chase Cancer Center 21
Large-scale testing (Phase 3)Study completedNCT01968213
What this trial is testing

Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3)

Who this might be right for
Ovarian CancerFallopian Tube CancerPeritoneal Cancer
pharmaand GmbH 564
Testing effectiveness (Phase 2)Active Not RecruitingNCT04713514
What this trial is testing

OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC

Who this might be right for
Platinum-sensitive Ovarian CancerRelapsed Ovarian Cancer
ARCAGY/ GINECO GROUP 180
Testing effectiveness (Phase 2)Study completedNCT02983799
What this trial is testing

Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status

Who this might be right for
Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
AstraZeneca 272
Not applicableUnknownNCT01851746
What this trial is testing

Docetaxel and Lobaplatin Versus Docetaxel and Carboplatin Combination Regimen in Patients With Platinum-sensitive (>6 Months) Relapsed Ovarian Cancer

Who this might be right for
Recurrent Ovarian Cancer
Wuhan University 200
Testing effectiveness (Phase 2)WithdrawnNCT01624493
What this trial is testing

BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients

Who this might be right for
Ovarian Cancer
Hoosier Cancer Research Network
Testing effectiveness (Phase 2)Ended earlyNCT01035658
What this trial is testing

Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal Adenocarcinoma

Who this might be right for
Ovarian CancerFallopian Tube CancerPeritoneal Carcinoma
SCRI Development Innovations, LLC 22
Testing effectiveness (Phase 2)Study completedNCT03657966
What this trial is testing

DCVAC/OvCa After Standard-of-care Chemotherapy in Women With Relapse of Platinum-sensitive Epithelial Ovarian Cancer

Who this might be right for
Ovarian Cancer Recurrent
SOTIO a.s. 33
Post-approval studies (Phase 4)Study completedNCT02476968
What this trial is testing

To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer

Who this might be right for
BRCA or HRR+ Mutated Ovarian Cancer Patients
AstraZeneca 181
Testing effectiveness (Phase 2)Ended earlyNCT01137071
What this trial is testing

Consolidation Therapy With Hu3S193 for Women With Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Who this might be right for
Fallopian Tube CancerOvarian CancerPeritoneal Cavity Cancer
Recepta Biopharma 29
Large-scale testing (Phase 3)Study completedNCT03863860
What this trial is testing

A Trial of Maintenance Treatment With Fluzoparib Versus Placebo in Relapsed Ovarian Cancer Patients

Who this might be right for
Ovarian Cancer
Jiangsu HengRui Medicine Co., Ltd. 252
Large-scale testing (Phase 3)WithdrawnNCT02392676
What this trial is testing

Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations

Who this might be right for
Platinum Sensitive Relapsed Ovarian Cancer
AstraZeneca
Next Page